PO.TB10.10 · 肿瘤生物学

CXCL13的分泌和固定在次级和三级淋巴结构(TLS)内显示出不同的地理分布

CXCL13 secretion and immobilization show distinct geographies within secondary and tertiary lymphoid structures (TLS)

海报缩略图:CXCL13的分泌和固定在次级和三级淋巴结构(TLS)内显示出不同的地理分布
编号 2219 展板 5 时间 4/20 09:00–12:00 区域 Section 31 主讲 Jonathan Skidmore, BS
分会场 Tertiary Lymphoid Structures in Cancer
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Jonathan Rex Skidmore, Aleksandra Ogurtsova, Grant Salvucci, Victoria Jacobs, Logan Engle, Robert A. Anders, Drew M. Pardoll, Janis Marie Taube

Johns Hopkins Bloomberg-Kimmel Inst. for Cancer Immunotherapy, Baltimore, MD

摘要 Abstract

中文摘要
本研究的目的是通过界定肿瘤组织中CXCL13趋化因子梯度的机制和空间模式,研究TLS中生发中心的形成和维持。在次级淋巴组织中,已知CXCL13被滤泡树突状细胞(FDCs)固定,但固定的机制仍不清楚。此外,TLS中CXCL13固定的空间模式和机制尚不明确。我们开发了一种CXCL13免疫组化/原位杂交(IHC/ISH)双重染色,以确定哪些细胞负责CXCL13的产生和展示。我们对3个福尔马林固定石蜡包埋扁桃体标本进行了染色,发现CXCL13蛋白和mRNA染色具有不同的定位。具体而言,对每个扁桃体的10个单独滤泡结构进行了空间分析,以比较通过IHC或ISH显示染色的生发中心或套区的表面积百分比(n=30)。该分析显示CXCL13蛋白在生发中心高表达,而在套区表达相对较低(表面积31% vs 12%,p<0.0001)。然而,CXCL13 ISH染色则相反:mRNA表达在生发中心较低,在套区较高(20% vs 37%,p<0.0001)。对新鲜扁桃体组织的流式细胞术分析显示,基质细胞展示CXCL13(PDPN+ CD31- CXCL13+),支持CXCL13 IHC的发现。类似地,空间转录组学显示出与CXCL13 ISH相似的发现,为该空间表达模式提供了额外验证。总之,这些结果支持一个模型,即CXCL13主要从套区分泌,然后在生发中心被固定。 为研究这些发现是否延伸至肿瘤组织中的TLS,我们将CXCL13 IHC/ISH双重染色应用于接受新辅助抗PD-1免疫治疗患者的根治性切除标本中的肺癌组织。空间分析显示,与在扁桃体中观察到的类似,CXCL13 mRNA的密度与CXCL13蛋白染色高度相关(n=3,Spearman's r:0.9,p<9.311e-19),尽管两者在空间上并不立即重叠,mRNA与蛋白表达之间的平均距离为30 μm,提示捕获了扩散中的CXCL13。我们还观察到成熟TLS中的基质细胞固定CXCL13,但未成熟TLS中的基质细胞则不固定。此外,我们发现CXCL13被固定在mRNA染色附近的弹性蛋白纤维上。 这些发现表明CXCL13的固定可能有助于TLS的形成和维持。通过调节CXCL13来增强TLS形成和成熟的新疗法可能值得探索。正在进行的单细胞RNA测序和体外研究正致力于确定负责淋巴和肿瘤组织中CXCL13固定的机制。
查看英文原文 English abstract
The purpose of this study is to investigate the formation and maintenance of germinal centers in TLS by defining mechanisms and spatial patterns of CXCL13 chemokine gradients in tumor tissue. In secondary lymphoid tissue, it is recognized that CXCL13 is immobilized by follicular dendritic cells (FDCs), but the mechanisms of immobilization remain unclear. Furthermore, spatial patterns and mechanisms of CXCL13 immobilization in TLS are unknown. We developed a CXCL13 Immunohistochemistry /in situ hybridization (ICH/ISH) dual stain to determine which cells are responsible for CXCL13 production and display. We stained 3 formalin-fixed paraffin-embedded tonsil specimens and found that CXCL13 protein and mRNA staining have distinct localizations. Specifically, spatial analyses were performed on 10 individual follicular structures from each tonsil to compare the percent surface area of either germinal centers or mantle zones (n=30) demonstrating staining by IHC or ISH. This analysis revealed that CXCL13 protein was highly expressed in germinal centers and expressed relatively lower in mantle zones (31% vs 12% surface area, p<0.0001). However, CXCL13 ISH staining was the inverse: mRNA expression was lower in germinal centers, and higher in mantle zones (20% vs 37%, p<0.0001). Flow cytometry analysis of fresh tonsil tissue revealed stromal cells displaying CXCL13, (PDPN + CD31 - CXCL13 + ), supporting the CXCL13 IHC findings. Similarly, spatial transcriptomics showed similar findings to the CXCL13 ISH, providing additional validation of the spatial expression pattern. Together, these results support a model where CXCL13 is primarily secreted from mantle zones, then immobilized in germinal centers. To investigate if these findings extend to TLS in tumor tissues, we applied our CXCL13 IHC/ISH dual stain to lung cancer tissue from the definitive resection specimen from patients treated with neoadjuvant anti-PD-1 immunotherapy. Spatial analyses revealed that similar to what was observed in tonsil, the density of CXCL13 mRNA is highly correlated with CXCL13 protein staining (n=3, Spearman's r: 0.9, p<9.311e-19), though these do not immediately overlap spatially, with an average distance of 30 μm between mRNA and protein expression, suggesting capture of the diffusing CXCL13. We also observed that stromal cells in mature TLS immobilize CXCL13, but stromal cells in immature TLS do not. In addition, we found CXCL13 immobilized on elastin fibers near mRNA staining. These findings show that CXCL13 immobilization may contribute to the formation and maintenance of TLS. New therapies enhancing the formation and maturation of TLS by modulating CXCL13 may warrant exploration. Ongoing single cell RNA sequencing and in vitro studies are focused on determining the mechanisms responsible for the immobilization of CXCL13 in lymphoid and tumor tissue.
利益披露 Disclosure
J. R. Skidmore, None.. A. Ogurtsova, None.. G. Salvucci, None.. V. Jacobs, None.. L. Engle, None.. R. A. Anders, None.. J. M. Taube, None.

← 返回 AACR 2026 检索